RxDoctor Payments Data

Peter Nguy, MD

Otolaryngology · Rancho Mirage, CANPI 1932632395

Payments from drug & device makers

$1,920in general payments, 2019–2025

Across 55 payments — averaging $34.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$600
  • Sanofi$511
  • GSK$175
  • Hologic Sales And Service, LLC$153
  • CSL Behring$150
  • Optinose US, Inc.$81
  • plus $248 from 7 others

What the payments were for

  • Food & beverage$1,920100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,920 in reported general payments places this provider in the 60th percentile of 1,021 otolaryngology providers in California.

See all otolaryngology providers in California

Medicare billing

Part B allowed, 2024
$101,007
Medicare patients
242
Services billed
794

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucalaMepolizumab16$58,683
Fluticasone Propionate295$4,317
Azelastine Hcl91$2,629
Ipratropium Bromide68$2,461
Ofloxacin32$806
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth11$789
Fluocinolone Acetonide Oil13$574
Famotidine29$557
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav34$544
Triamcinolone Acetonide18$526
Clotrimazole27$479
Mupirocin33$226
Methylprednisolone27$165
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen24$119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala$175$58,68316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,021 otolaryngology providers in California.

Other otolaryngology in Rancho Mirage

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →